Predictive Factors for Adverse Dermatological Events During Pegylated/Interferon Alpha and Ribavirin Treatment for Hepatitis C

    April 2014 in “ Journal of Clinical Virology ”
    Zhengxiao Li, Yanfei Zhang, Jingang An … Fanpu Ji
    Studysummary This study found that dermatological adverse events from interferon-alpha/ribavirin treatment for chronic hepatitis C are associated with factors like older age, pre-existing skin conditions, cirrhosis, and the use of pegylated interferon formulations.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Cutaneous Reactions in Patients with Chronic Hepatitis C Treated with Peginterferon and Ribavirin Dermatology · 2014
    2. A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin Canadian Journal of Gastroenterology · 2009
    3. Reversible Alopecia Universalis Secondary to PEG-Interferon Alpha-2b and Ribavirin Combination Therapy in a Patient with Chronic Hepatitis C Virus Infection European Journal of Gastroenterology & Hepatology · 2007
    4. Cutaneous Necrosis After Injection of Polyethylene Glycol–Modified Interferon Alfa Journal of The American Academy of Dermatology · 2005